Alemtuzumab in the Long-Term Treatment of Relapsing-Remitting Multiple Sclerosis: An Update on the Clinical Trial Evidence and Data From the Real World

Therapeutic Advances in Neurological Disorders - United Kingdom
doi 10.1177/1756285617722706
Full Text
Abstract

Available in full text

Date
Authors
Publisher

SAGE Publications

Related search

Alemtuzumab: Evidence for Its Potential in Relapsing–remitting Multiple Sclerosis

Drug Design, Development and Therapy
Drug DiscoveryPharmacologyPharmaceutical Science
2013English

Alemtuzumab: A Review of Efficacy and Risks in the Treatment of Relapsing Remitting Multiple Sclerosis

Therapeutics and Clinical Risk Management
2017English

Efficacy of Natalizumab and Fingolimod in Relapsing Remitting Multiple Sclerosis in Real World Clinical Setting

Journal of Neurology & Neurophysiology
2015English

Long-Term Safety and Real-World Effectiveness of Fingolimod in Relapsing Multiple Sclerosis

Patient Related Outcome Measures
2017English

The Real-World Effectiveness and Safety of Fingolimod in Relapsing-Remitting Multiple Sclerosis Patients: An Observational Study

PLoS ONE
Multidisciplinary
2017English

Pnd13 - Real World Evidence (Rwe) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (Dmts) in Relapsing-Remitting Multiple Sclerosis (Rrms) in Australia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

049 Real World Evidence (RWE) on Impact of Age on Long-Term Persistence to Disease Modifying Therapies (DMTS) in Relapsing-Remitting Multiple Sclerosis (RRMS) in Australia

Journal of Neurology, Neurosurgery and Psychiatry
PsychiatryMental HealthNeurologySurgery
2019English

Long-Term Safety and Efficacy of Natalizumab in Relapsing-Remitting Multiple Sclerosis: Impact on Quality of Life

Patient Related Outcome Measures
2014English

Cost-Effectiveness of Cladribine Tablets, Alemtuzumab and Natalizumab in the Treatment of Relapsing-Remitting Multiple Sclerosis With High Disease Activity in England

Journal of Medical Economics
Health Policy
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy